AVANT’s Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints In Phase 2 Study

AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced that the double-blind, placebo-controlled multi-center Phase 2 clinical trial of its typhoid fever vaccine candidate, Ty800, met all primary endpoints. The Phase 2 study was an out-patient, dose-ranging clinical trial in 183 healthy volunteers that evaluated two dose levels of the Ty800 vaccine and followed each subject for six months post-vaccination.

More: continued here

Filed under: Clinical Trials on April 4th, 2008